1
|
Zhang S, Cai Z, Li H. AHNAKs roles in physiology and malignant tumors. Front Oncol 2023; 13:1258951. [PMID: 38033502 PMCID: PMC10682155 DOI: 10.3389/fonc.2023.1258951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 10/30/2023] [Indexed: 12/02/2023] Open
Abstract
The AHNAK family currently consists of two members, namely AHNAK and AHNAK2, both of which have a molecular weight exceeding 600 kDa. Homologous sequences account for approximately 90% of their composition, indicating a certain degree of similarity in terms of molecular structure and biological functions. AHNAK family members are involved in the regulation of various biological functions, such as calcium channel modulation and membrane repair. Furthermore, with advancements in biological and bioinformatics technologies, research on the relationship between the AHNAK family and tumors has rapidly increased in recent years, and its regulatory role in tumor progression has gradually been discovered. This article briefly describes the physiological functions of the AHNAK family, and reviews and analyzes the expression and molecular regulatory mechanisms of the AHNAK family in malignant tumors using Pubmed and TCGA databases. In summary, AHNAK participates in various physiological and pathological processes in the human body. In multiple types of cancers, abnormal expression of AHNAK and AHNAK2 is associated with prognosis, and they play a key regulatory role in tumor progression by activating signaling pathways such as ERK, MAPK, Wnt, and MEK, as well as promoting epithelial-mesenchymal transition.
Collapse
Affiliation(s)
- Shusen Zhang
- Hebei Province Xingtai People’s Hospital Postdoctoral Workstation, Xingtai, China
- Postdoctoral Mobile Station, Hebei Medical University, Shijiazhuang, China
- Department of Pulmonary and Critical Care Medicine, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai, China
- The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China
| | - Zhigang Cai
- Postdoctoral Mobile Station, Hebei Medical University, Shijiazhuang, China
- The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China
| | - Hui Li
- Department of surgery, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai, China
| |
Collapse
|
2
|
Sales LP, Hounkpe BW, Perez MO, Caparbo VF, Domiciano DS, Borba EF, Schett G, Figueiredo CP, Pereira RMR. Transcriptomic characterization of classical monocytes highlights the involvement of immuno-inflammation in bone erosion in Rheumatoid Arthritis. Front Immunol 2023; 14:1251034. [PMID: 37868981 PMCID: PMC10588645 DOI: 10.3389/fimmu.2023.1251034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 09/21/2023] [Indexed: 10/24/2023] Open
Abstract
Introduction Evidence-based data suggest that under inflammatory conditions, classical monocytes are the main source of osteoclasts and might be involved in bone erosion pathophysiology. Here, we analyze the transcriptomic profile of classical monocytes in erosive and non-erosive rheumatoid arthritis patients in order to better understand their contribution to bone erosion. Methods Thirty-nine premenopausal RA patients were consecutively enrolled and divided into two groups based on the presence of bone erosions on hand joints. Classical monocytes were isolated from peripheral blood through negative selection, and RNA-seq was performed using a poly-A enrichment kit and Illumina® platform. Classical monocytes transcriptome from healthy age-matched women were also included to identify differentially expressed genes (DEGs). Therefore, gene sets analysis was performed to identify the enriched biological pathways. Results RNA-seq analysis resulted in the identification of 1,140 DEGs of which 89 were up-regulated and 1,051 down-regulated in RA patients with bone erosion compared to those without bone erosions. Among up-regulated genes, there was a highlighted expression of IL18RAP and KLF14 related to the production of pro-inflammatory cytokines, innate and adaptive immune response. Genes related to collagen metabolism (LARP6) and bone formation process (PAPPA) were down-regulated in RA patients with erosions. Enriched pathways in patients with erosions were associated with greater activation of immune activation, and inflammation. Interestingly, pathways associated with osteoblast differentiation and regulation of Wnt signaling were less activated in RA patients with erosions. Conclusion These findings suggest that alterations in expression of monocyte genes related to the inflammatory process and impairment of bone formation might have an important role in the pathophysiology of bone erosions in RA patients.
Collapse
Affiliation(s)
- Lucas Peixoto Sales
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Bidossessi Wilfried Hounkpe
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Mariana Ortega Perez
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Valéria Falco Caparbo
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Diogo Souza Domiciano
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Eduardo Ferreira Borba
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Georg Schett
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Camille Pinto Figueiredo
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | - Rosa Maria Rodrigues Pereira
- Rheumatology Division, Bone Metabolism Laboratory, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
4
|
Biswas B, Guemiri R, Cadix M, Labbé CM, Chakraborty A, Dutertre M, Robert C, Vagner S. Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition. Cancers (Basel) 2022; 14:cancers14051177. [PMID: 35267483 PMCID: PMC8909304 DOI: 10.3390/cancers14051177] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 02/20/2022] [Accepted: 02/21/2022] [Indexed: 02/05/2023] Open
Abstract
Targeting the translation initiation complex eIF4F, which binds the 5' cap of mRNAs, is a promising anti-cancer approach. Silvestrol, a small molecule inhibitor of eIF4A, the RNA helicase component of eIF4F, inhibits the translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor, which, in turn, reduces the transcription of the gene encoding one of the major immune checkpoint proteins, i.e., programmed death ligand-1 (PD-L1) in melanoma cells. A large proportion of human genes produce multiple mRNAs differing in their 3'-ends through the use of alternative polyadenylation (APA) sites, which, when located in alternative last exons, can generate protein isoforms, as in the STAT1 gene. Here, we provide evidence that the STAT1α, but not STAT1β protein isoform generated by APA, is required for silvestrol-dependent inhibition of PD-L1 expression in interferon-γ-treated melanoma cells. Using polysome profiling in activated T cells we find that, beyond STAT1, eIF4A inhibition downregulates the translation of some important immune-related mRNAs, such as the ones encoding TIM-3, LAG-3, IDO1, CD27 or CD137, but with little effect on the ones for BTLA and ADAR-1 and no effect on the ones encoding CTLA-4, PD-1 and CD40-L. We next apply RT-qPCR and 3'-seq (RNA-seq focused on mRNA 3' ends) on polysomal RNAs to analyze in a high throughput manner the effect of eIF4A inhibition on the translation of APA isoforms. We identify about 150 genes, including TIM-3, LAG-3, AHNAK and SEMA4D, for which silvestrol differentially inhibits the translation of APA isoforms in T cells. It is therefore crucial to consider 3'-end mRNA heterogeneity in the understanding of the anti-tumor activities of eIF4A inhibitors.
Collapse
Affiliation(s)
- Biswendu Biswas
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
- INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France;
- Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France
| | - Ramdane Guemiri
- INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France;
- Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France
| | - Mandy Cadix
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
| | - Céline M. Labbé
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
| | - Alina Chakraborty
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
| | - Martin Dutertre
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
| | - Caroline Robert
- INSERM U981, Gustave Roussy Cancer Campus, 94805 Villejuif, France;
- Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France
- Correspondence: (C.R.); (S.V.)
| | - Stéphan Vagner
- Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, 91401 Orsay, France; (B.B.); (M.C.); (C.M.L.); (A.C.); (M.D.)
- Biologie de l’ARN, Signalisation et Cancer, Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, 91401 Orsay, France
- Équipe Labellisée Ligue Contre le Cancer, 91401 Orsay, France
- Correspondence: (C.R.); (S.V.)
| |
Collapse
|
5
|
Zardab M, Stasinos K, Grose RP, Kocher HM. The Obscure Potential of AHNAK2. Cancers (Basel) 2022; 14:cancers14030528. [PMID: 35158796 PMCID: PMC8833689 DOI: 10.3390/cancers14030528] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 01/17/2022] [Accepted: 01/18/2022] [Indexed: 12/17/2022] Open
Abstract
Simple Summary AHNAK2 is a relatively newly discovered protein. It can interact with many other proteins. This protein is increased in cells of variety of different cancers. AHNAK2 may play a vital role in cancer formation. AHNAK2 may have a role in early detection of cancer. This obscure potential of AHNAK2 is being studied. Abstract AHNAK2 is a protein discovered in 2004, with a strong association with oncogenesis in various epithelial cancers. It has a large 616 kDa tripartite structure and is thought to take part in the formation of large multi-protein complexes. High expression is found in clear cell renal carcinoma, pancreatic ductal adenocarcinoma, uveal melanoma, and lung adenocarcinoma, with a relation to poor prognosis. Little work has been done in exploring the function and relation AHNAK2 has with cancer, with early studies showing promising potential as a future biomarker and therapeutic target.
Collapse
|
6
|
He Y, Fang Y, Zhai B, Liu X, Zhu G, Zhou S, Xu Y, Wang X, Su W, Wang R. Gm40600 promotes CD4 + T-cell responses by interacting with Ahnak. Immunology 2021; 164:190-206. [PMID: 33987830 PMCID: PMC8358717 DOI: 10.1111/imm.13365] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 04/11/2021] [Accepted: 04/29/2021] [Indexed: 12/31/2022] Open
Abstract
It is important to characterize novel proteins involved in T- and B-cell responses. Our previous study demonstrated that a novel protein, Mus musculus Gm40600, reduced the proliferation of Mus musculus plasmablast (PB)-like SP 2/0 cells and B-cell responses induced in vitro by LPS. In the present study, we revealed that Gm40600 directly promoted CD4+ T-cell responses to indirectly up-regulate B-cell responses. Importantly, we found that CD4+ T-cell responses, including T-cell activation and differentiation and cytokine production, were increased in Gm40600 transgenic (Tg) mice and were reduced in Gm40600 knockout (KO) mice. Finally, we demonstrated that Gm40600 promoted the Ahnak-mediated calcium signalling pathway by interacting with Ahnak to maintain a cytoplasmic lateral location of Ahnak in CD4+ T cells. Collectively, our data suggest that Gm40600 promotes CD4+ T-cell activation to up-regulate the B-cell response via interacting with Ahnak to promote the calcium signalling pathway. The results suggest that targeting Gm40600 may be a means to control CD4+ T-cell-related diseases.
Collapse
Affiliation(s)
- Youdi He
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
- Department of NeurologyBeijing Chaoyang HospitalCapital Medical UniversityBeijingChina
| | - Ying Fang
- Department of RheumatologyFirst Hospital of Jilin UniversityChangchunChina
| | - Bing Zhai
- Department of Geriatric HematologyChinese PLA General HospitalBeijingChina
| | - Xiaoling Liu
- Department of DermatologyFirst Medical Centre of ChinesePLA General HospitalBeijingChina
| | - Gaizhi Zhu
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
| | - Shan Zhou
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
| | - Yaqi Xu
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
| | - Xiaoqian Wang
- Staidson (Beijing) Biopharmaceuticals Co. LtdBeijingChina
| | - Wenting Su
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
| | - Renxi Wang
- Beijing Institute of Brain DisordersLaboratory of Brain DisordersMinistry of Science and TechnologyCollaborative Innovation Center for Brain DisordersCapital Medical UniversityBeijingChina
| |
Collapse
|